CommentaryTherapeutic potential of targeting mitochondrial dynamics in cancer
Under an Elsevier user license
open access
Graphical abstract
Representative illustration of the mitochondrial dynamics alterations induced by the BRAF inhibitor vemurafenib in melanoma cells.
Abbreviations
ATP
Adenosine triphosphate
BCL-2
B-cell lymphoma protein 2
BCL-xL
B-cell lymphoma-extra-large
BAK
Bcl-2 homologous antagonist/killer
βIIPKC
beta II protein kinase C
CAMKII
calcium/calmodulin-dependent kinase II
PKA
cAMP-dependent protein kinase
DRP1 or DNM1L
dynamin-1-like protein
ER
endoplasmic reticulum
ERK
extracellular signal-regulated kinase
GTPases
guanosine triphosphatases
L-OPA1
long optic atrophy 1
MFF
mitochondria fission factor
MCU
mitochondrial calcium uniporter
mtDNA
mitochondrial DNA
MID49 and MID51
mitochondrial dynamics protein of 49 kDa and 51 kDa
FIS1
mitochondrial fission 1 protein
MOMP
mitochondrial outer membrane permeabilization
MPT
mitochondrial permeability transition
ΔΨ
mitochondrial transmembrane potential
MFN1
mitofusin 1
MFN2
mitofusin 2
MAPK
mitogen activated protein kinases
NCX
Na+/Ca2+ exchanger
OPA1
optic atrophy 1
OXPHOS
oxidative phosphorylation
PI3K
phosphoinositide 3-kinase
AKT
protein kinase B
RAF
rapidly accelerated fibrosarcoma
ROS
reactive oxygen species
S-OPA1
short optic atrophy 1
RAS
small GTPase rat sarcoma
Keywords
Bioenergetics
Cancer
Cell death
Chemotherapy
Mitochondrial dynamics
Cited by (0)
© 2020 Elsevier Inc.